Found: 30
Select item for more details and to access through your institution.
European regulatory policies on medicines and public health needs.
- Published in:
- European Journal of Public Health, 2003, v. 13, n. 3, p. 246, doi. 10.1093/eurpub/13.3.246
- By:
- Publication type:
- Article
Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 1, p. 170, doi. 10.1111/bcp.14130
- By:
- Publication type:
- Article
Orphan drug development is not taking off.
- Published in:
- British Journal of Clinical Pharmacology, 2009, v. 67, n. 5, p. 494, doi. 10.1111/j.1365-2125.2009.03369.x
- By:
- Publication type:
- Article
Thrombolysis or nothing for acute myocardial infarction? It's all the same!
- Published in:
- British Journal of Clinical Pharmacology, 2008, v. 65, n. 6, p. 955, doi. 10.1111/j.1365-2125.2008.03125.x
- By:
- Publication type:
- Article
Clinical evidence supporting the marketing authorization of biosimilars in Europe.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 4, p. 557, doi. 10.1007/s00228-019-02805-y
- By:
- Publication type:
- Article
Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study.
- Published in:
- European Journal of Preventive Cardiology, 2018, v. 25, n. 16, p. 1735, doi. 10.1177/2047487318770299
- By:
- Publication type:
- Article
Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 7, p. 537, doi. 10.2165/00019053-200826070-00001
- By:
- Publication type:
- Article
Older patients are still under-represented in clinical trials of Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2016, v. 8, p. 1, doi. 10.1186/s13195-016-0201-2
- By:
- Publication type:
- Article
Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines.
- Published in:
- European Journal of Clinical Pharmacology, 2018, v. 74, n. 3, p. 373, doi. 10.1007/s00228-017-2378-0
- By:
- Publication type:
- Article
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 4, p. 1009, doi. 10.1007/s00228-012-1423-2
- By:
- Publication type:
- Article
Placebo? no thanks, it might be bad for me!
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 3, p. 711, doi. 10.1007/s00228-012-1383-6
- By:
- Publication type:
- Article
EMA's reflection on placebo does not reflect patients' interests.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
Anything new in EU pharmacovigilance?
- Published in:
- 2011
- By:
- Publication type:
- Opinion
Limits of add-on trials: antirheumatic drugs.
- Published in:
- European Journal of Clinical Pharmacology, 2009, v. 65, n. 1, p. 33, doi. 10.1007/s00228-008-0545-z
- By:
- Publication type:
- Article
Enhancing the rational use of new medicines across European health care systems.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
Do we learn the right things from clinical trials?
- Published in:
- European Journal of Clinical Pharmacology, 2008, v. 64, n. 2, p. 115, doi. 10.1007/s00228-007-0411-4
- By:
- Publication type:
- Article
New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Haematological anticancer drugs in Europe: any added value at the time of approval?
- Published in:
- 2007
- By:
- Publication type:
- Letter
Efficacy, safety and cost of new cardiovascular drugs: a survey.
- Published in:
- European Journal of Clinical Pharmacology, 2003, v. 59, n. 8/9, p. 701, doi. 10.1007/s00228-003-0634-y
- By:
- Publication type:
- Article
Efficacy, safety and cost of new drugs acting on the central nervous system.
- Published in:
- European Journal of Clinical Pharmacology, 2003, v. 59, n. 1, p. 79, doi. 10.1007/s00228-003-0569-3
- By:
- Publication type:
- Article
Clinical research on rare diseases of children: neuroblastoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Orphan drug development is progressing too slowly.
- Published in:
- British Journal of Clinical Pharmacology, 2006, v. 61, n. 3, p. 355, doi. 10.1111/j.1365-2125.2006.02579.x
- By:
- Publication type:
- Article
Risk : benefit assessment of old medicines.
- Published in:
- British Journal of Clinical Pharmacology, 2004, v. 58, n. 6, p. 581, doi. 10.1111/j.1365-2125.2004.02197.x
- By:
- Publication type:
- Article
Health care: Make pharma justify the price of drugs.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
Informed consent: meet patients' needs.
- Published in:
- 2012
- By:
- Publication type:
- Letter
A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?
- Published in:
- 2017
- By:
- Publication type:
- journal article
Specific barriers to the conduct of randomised clinical trials on medical devices.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with?
- Published in:
- 2017
- By:
- Publication type:
- journal article
Barriers to the conduct of randomised clinical trials within all disease areas.
- Published in:
- 2017
- By:
- Publication type:
- journal article